cancer immunotherapy

German Merck Licenses Fusion Protein to PDS

Germany‘s Merck has granted an exclusive license for the tumor-targeting IL-12 fusion protein currently known as M9241 to PDS Biotechnology Corporation, a US-based clinical-stage immunotherapy company with a growing pipeline of targeted immunotherapies for cancer and infectious disease.

News

Merck, Ono To Jointly Develop Oral Multiple Sclerosis Drug, Cancer Immunotherapy

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

API Manufacturing

Nova-Institut GmbH

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

CHEManager International c/o Wiley-VCH GmbH

20 Years of CHEManager International

MOC – Event Center Messe München

A successful concept on course for expansion — maintenance Munich 2025

Concept Heidelberg

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Brenntag SE

Brenntag Downsizes Management Board, Retains Both Divisions

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.